Atara Biotherap (ATRA) Stock Price, Quote & News

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to tar...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States

ajmrtxl Sep. 8 at 3:55 PM

$ATRA 's latest data on SqueezeFinder

0 · Reply

FilingTracker Sep. 4 at 10:26 PM

$ATRA $1 million insider purchase: https://filingtracker.ai/filing/1604464/0000905148-26-004085

0 · Reply

Dimon11 Aug. 27 at 2:34 PM

$ATRA what the new form? Who sold or bought?

0 · Reply

Pharoh42 Aug. 6 at 12:01 AM

$ATRA Helloooo Anybody here

0 · Reply

Pharoh42 Jul. 14 at 8:00 PM

$ATRA What is the deal here ?

0 · Reply

Pharoh42 Jul. 6 at 8:59 PM

$ATRA The minute I get frustrated with this pos it will shoot , pretty sure.

0 · Reply

JuggernautRaider Jul. 1 at 8:09 AM

$BOLD $ATRA i cannot wait to short these turds. Flush the toilet!🚽

0 · Reply

TheYoungGeologist Jun. 30 at 12:39 PM

$UNCY weird ass decision, FDA failure just like with $ATRA . Sorry for anyone that had shares

0 · Reply

Pharoh42 Jun. 23 at 11:47 AM

$ATRA someone is making fuck you money of this daily rollercoaster of a stock

0 · Reply

JuggernautRaider Jun. 15 at 10:46 PM

$ATRA

1 · Reply

Atara Biotherapeutics reports Q2 EPS (32c), consensus (32c)

Aug 12, 2026, 4:05 PM EDT - 4 weeks ago

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Atara Biotherapeutics Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 4 weeks ago

Atara Biotherapeutics Earnings release: Q2 2026

Jun 12, 2026, 4:00 PM EDT - 2 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Jun 11, 2026, 6:52 AM EDT - 3 months ago

Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia

Jun 9, 2026, 12:00 PM EDT - 3 months ago

Atara Biotherapeutics Transcript: AGM 2026

2026-05-18T14:20:09.000Z - 3 months ago

Atara Biotherapeutics upgraded to Hold from Sell at Freedom Broker

2026-05-12T21:59:07.000Z - 4 months ago

Atara Biotherapeutics reports Q1 EPS -29c, consensus -22c

May 12, 2026, 4:05 PM EDT - 4 months ago

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

May 12, 2026, 7:00 AM EDT - 4 months ago

Atara Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Atara Biotherapeutics Earnings release: Q1 2026

2026-05-08T08:50:11.000Z - 4 months ago

Atara Biotherapeutics upgraded to Buy from Hold at Canaccord

2026-05-07T18:17:49.000Z - 4 months ago

Atara Biotherapeutics trading halted, volatility trading pause

2026-05-07T18:16:36.000Z - 4 months ago

Atara Biotherapeutics jumps 70%, or $3.60, to $8.75

2026-05-07T18:14:10.000Z - 4 months ago

Atara Biotherapeutics trading resumes

2026-05-07T13:09:48.000Z - 4 months ago

Atara says PFP had productive meeting with FDA

2026-05-07T13:00:26.000Z - 4 months ago

Why Is Atara Biotherapeutics Stock (ATRA) Up Today?

May 7, 2026, 8:05 AM EDT - 4 months ago

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Atara Biotherapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Atara Biotherapeutics Proxy statement: Proxy filing

Apr 16, 2026, 6:10 PM EDT - 4 months ago

ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 7, 2026, 6:00 PM EDT - 5 months ago

ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role

2026-03-17T20:20:37.000Z - 5 months ago

Atara Biotherapeutics files to sell 400K shares of common stock for holders

Mar 17, 2026, 8:00 AM EDT - 5 months ago

Atara Biotherapeutics Registration statement: Registration Filing

Mar 16, 2026, 4:05 PM EDT - 5 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Mar 16, 2026, 4:00 PM EDT - 5 months ago

Atara Biotherapeutics Earnings release: Q4 2025

Mar 16, 2026, 4:00 PM EDT - 5 months ago

Atara Biotherapeutics Annual report: Q4 2025

2026-03-12T12:45:52.000Z - 6 months ago

Atara provides update on tabelecleucel biologics license application

2026-03-03T13:10:42.000Z - 6 months ago

Atara Biotherapeutics partner submits Type A meeting request to FDA

2026-02-23T13:15:10.000Z - 6 months ago

Atara Biotherapeutics amends HealthCare Royalty purchase, sale agreement

Feb 23, 2026, 8:00 AM EST - 6 months ago

Atara Biotherapeutics Provides a Business Update

2026-01-13T18:40:59.000Z - 7 months ago

Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)

2026-01-12T13:37:46.000Z - 8 months ago

FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form

Jan 12, 2026, 8:00 AM EST - 8 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

2026-01-08T15:34:07.000Z - 8 months ago

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears

2025-12-19T11:31:07.000Z - 8 months ago

Atara Biotherapeutics price target raised to $25 from $17 at Canaccord

Nov 12, 2025, 9:00 AM EST - 10 months ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 12, 2025, 9:00 AM EST - 10 months ago

Atara Biotherapeutics Quarterly report: Q3 2025

Nov 12, 2025, 9:00 AM EST - 10 months ago

Atara Biotherapeutics Earnings release: Q3 2025

Nov 3, 2025, 9:00 AM EST - 10 months ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Aug 18, 2025, 7:00 AM EDT - 1 year ago

Atara Biotherapeutics Quarterly report: Q2 2025

Aug 18, 2025, 7:00 AM EDT - 1 year ago

Atara Biotherapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Jul 24, 2025, 8:57 AM EDT - 1 year ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jun 10, 2025, 12:00 PM EDT - 1 year ago

Atara Biotherapeutics Transcript: AGM 2025

May 16, 2025, 8:50 PM EDT - 1 year ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 15, 2025, 8:35 AM EDT - 1 year ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Earnings release: Q1 2025

May 5, 2025, 5:06 PM EDT - 1 year ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Atara Biotherapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Atara Biotherapeutics Proxy statement: Proxy Filing

Mar 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 9:30 AM EST - 1 year ago

Atara Biotherapeutics Annual report: Q4 2024

Mar 7, 2025, 9:30 AM EST - 1 year ago

Atara Biotherapeutics Earnings release: Q4 2024

Feb 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ajmrtxl Sep. 8 at 3:55 PM

$ATRA 's latest data on SqueezeFinder

0 · Reply

FilingTracker Sep. 4 at 10:26 PM

$ATRA $1 million insider purchase: https://filingtracker.ai/filing/1604464/0000905148-26-004085

0 · Reply

Dimon11 Aug. 27 at 2:34 PM

$ATRA what the new form? Who sold or bought?

0 · Reply

Pharoh42 Aug. 6 at 12:01 AM

$ATRA Helloooo Anybody here

0 · Reply

Pharoh42 Jul. 14 at 8:00 PM

$ATRA What is the deal here ?

0 · Reply

Pharoh42 Jul. 6 at 8:59 PM

$ATRA The minute I get frustrated with this pos it will shoot , pretty sure.

0 · Reply

JuggernautRaider Jul. 1 at 8:09 AM

$BOLD $ATRA i cannot wait to short these turds. Flush the toilet!🚽

0 · Reply

TheYoungGeologist Jun. 30 at 12:39 PM

$UNCY weird ass decision, FDA failure just like with $ATRA . Sorry for anyone that had shares

0 · Reply

Pharoh42 Jun. 23 at 11:47 AM

$ATRA someone is making fuck you money of this daily rollercoaster of a stock

0 · Reply

JuggernautRaider Jun. 15 at 10:46 PM

$ATRA

1 · Reply

Pharoh42 Jun. 12 at 10:55 PM

$ATRA It is waiting for something

0 · Reply

Pharoh42 Jun. 2 at 10:06 AM

$ATRA I am not selling out of frustration as usual because I know I will wake up one day and this turd unexpectedly up 200%

1 · Reply

jadeite_haystack May. 28 at 8:44 PM

$ATRA

0 · Reply

robanbieber May. 28 at 8:33 PM

$ATRA

0 · Reply

Prettyricky13 May. 22 at 10:50 AM

$ATRA dam this is still holding no dilution this going to pop on any update of resubmission but when it pops they will dilute so don’t be greedy

0 · Reply

Ftruck May. 22 at 1:20 AM

$ATRA I have been sitting on this stock for 11 days, come on

0 · Reply

jimmy18000 May. 18 at 6:33 PM

$ATRA Agreed. This has shown some resilience. And any news on BLA resubmission will catapult pps to the teens.

0 · Reply

robanbieber May. 13 at 7:54 PM

$ATRA The Atara executives are already being sued for making false statements a year ago which caused a 60% plus drop in the stock earlier this year.... the fact that they are currently diluting the stock at $10/share on such a failure of an ER is another crime that retailers are falling victim to.... shame....

1 · Reply

topstockalerts May. 13 at 1:59 AM

$ATRA that move had a lot more substance than I expected.

0 · Reply

robanbieber May. 12 at 9:56 PM

$ATRA with the bad earnings report with loss of 29c per share , huge miss of sales with only $516K of estimated $2.85M and a $79.3 million dilution just announced .... , bulls should take there winnings now before they evaporate....

1 · Reply

robanbieber May. 12 at 9:38 PM

$ATRA I need to correct this... 79 million dollars worth of shares can be dumped so roughly between 7-10 million shares depending on when they can dump them into the market...

0 · Reply

robanbieber May. 12 at 9:02 PM

$ATRA there it is ... the offfering just like predicted.... 79 million shares dumped.... going back down....

0 · Reply

Market Cap	102.69M
Revenue (ttm)	120.77M
Net Income (ttm)	32.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	27.07%
Debt to Equity Ratio	0.00

Volume	68,500
Avg Vol	62,338
Day's Range	N/A - N/A
Shares Out	10.04M
Stochastic %K	44%
Beta	0.10
Analysts	Sell
Price Target	$13.67